Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021 August 23, 2021
Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors July 30, 2021
Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress July 1, 2021
Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer Cells May 13, 2021
